E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Add to balance / Manage account  User:  Log out
Prospect News home > News index > List of issuers O > Headlines for Oscient Pharmaceuticals Corp. > News item
Published on 9/26/2006 in the Prospect News Biotech Daily and Prospect News Convertibles Daily.

Oscient Pharmaceuticals files $100 million shelf registration

By Laura Lutz

Des Moines, Sept. 26 - Oscient Pharmaceuticals Corp. filed a $100 million shelf registration in an S-3 filing with the Securities and Exchange Commission.

The registration covers common stock, debt securities and warrants. The securities may be structured as convertibles.

Proceeds will be used for general corporate purposes.

Oscient is a biopharmaceutical company based in Waltham, Mass.


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.